Search

Your search keyword '"de Cuba, Erienne M V"' showing total 11 results
Start Over Author "de Cuba, Erienne M V"
11 results on '"de Cuba, Erienne M V"'

1. Transanal minimally invasive surgery (TAMIS) versus endoscopic submucosal dissection (ESD) for resection of non-pedunculated rectal lesions (TRIASSIC study): study protocol of a European multicenter randomised controlled trial

Author

Dekkers, Nik, Boonstra, Jurjen J., Moons, Leon M. G., Hompes, Roel, Bastiaansen, Barbara A., Tuynman, Jurriaan B., Koch, Arjun D., Weusten, Bas L. A. M., Pronk, Apollo, Neijenhuis, Peter A., Westerterp, Marinke, van den Hout, Wilbert B., Langers, Alexandra M. J., van der Kraan, Jolein, Alkhalaf, Alaa, Lai, Jonathan Y. L., ter Borg, Frank, Fabry, Hans, Halet, Eric, Schwartz, Matthijs P., Nagengast, Wouter B., Straathof, Jan Willem A., ten Hove, Rogier W. R., Oterdoom, Leendert H., Hoff, Christiaan, Belt, Eric J Th, Zimmerman, David D. E., Hadithi, Muhammed, Morreau, Hans, de Cuba, Erienne M. V., Leijtens, Jeroen W. A., Vasen, Hans F. A., van Leerdam, Monique E., de Graaf, Eelco J. R., Doornebosch, Pascal G., and Hardwick, James C. H.

Published
2020
Full Text
View/download PDF

3. A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9

Author

Goos, Jeroen A. C. M., Coupe, Veerle M. H., van de Wiel, Mark A., Diosdado, Begona, Delis-Van Diemen, Pien M., Hiemstra, Annemieke C., de Cuba, Erienne M. V., Belien, Jeroen A. M., Geldof, Albert A., Meijer, Gerrit A., Hoekstra, Otto S., Fijneman, Remond J. A., Menke, C. W., Pathology, Epidemiology and Data Science, CCA - Biomarkers, Other Research, Urology, Radiology and nuclear medicine, and Medical oncology

Published
2016

4. Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis

Author

Goos, Jeroen A C M, de Cuba, Erienne M V, Coupé, Veerle M H, Diosdado, Begoña, Delis-Van Diemen, Pien M, Karga, Cemile, Beliën, Jeroen A M, Menke-Van der Houven van Oordt, C Willemien, Geldof, Albert A, Meijer, Gerrit A, Hoekstra, Otto S, Fijneman, Remond J A, DeCoDe PET Group, Lam, MGEH, Borel Rinkes, IHM, van Diest, PJ, van Hillegersberg, R, and Kranenburg, OW

Subjects
VEGFA, Vascular Endothelial Growth Factor A, Glucose Transporter Type 1, Research Support, Non-U.S. Gov't, Liver Neoplasms, SLC2A1, HIF1, colorectal cancer, Hypoxia-Inducible Factor 1, alpha Subunit, Survival Rate, liver metastasis, Journal Article, Colorectal Neoplasms, prognostic biomarker
Abstract

OBJECTIVE: To investigate the individual and combined prognostic value of HIF1α, SLC2A1, and vascular endothelial growth factor A (VEGFA) in a multi-institutional cohort of patients with resected colorectal cancer liver metastasis (CRCLM). BACKGROUND: In the majority of patients with CRCLM, resection seems not to be curative, despite its curative intent. Overexpression of hypoxia-inducible factor 1α (HIF1α), glucose transporter 1 (SLC2A1; also known as GLUT1), and VEGFA has been associated with tumor progression and poor prognosis of patients with colorectal cancer (CRC). METHODS: Tissue microarrays were generated using CRCLM and patient-matched primary CRC from patients who underwent CRCLM resection between 1990 and 2010. Prognostic value of HIF1α, SLC2A1, and VEGFA was determined by immunohistochemistry. A 500-fold cross-validated hazard rate ratio (HRRav) for overall survival was calculated. RESULTS: HIF1α, SLC2A1, and VEGFA expression could be evaluated in 328, 350, and 335 patients, respectively. High SLC2A1 expression was associated with good prognosis (HRRav, 0.67; P (HRR >1) < 0.01) and high VEGFA expression to poor prognosis (HRRav, 1.84; P (HRR < 1) = 0.02), also after multivariate analysis including established clinicopathological prognostic variables (HRRav, 0.67; P (HRR > 1) < 0.01 and HRRav, 1.50; P (HRR < 1) = 0.02, respectively). SLC2A1 showed prognostic value particularly in patients treated with systemic therapy (P < 0.01), whereas the prognostic value of VEGFA expression was mainly observed in patients not treated with systemic therapy (P < 0.01). Prognosis was especially poor in patients with both low SLC2A1 and high VEGFA expression (P < 0.01). HIF1α expression was not associated with survival. CONCLUSIONS: SLC2A1 and VEGFA expression are prognostic molecular biomarkers for patients with CRCLM with added value to established clinicopathological variables.

Published
2016

5. Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis

Author

Researchgr. Nucleaire Geneeskunde, Cancer, MS CGO, Regenerative Medicine and Stem Cells, Pathologie, Divisie Beeld & Oncologie, Goos, Jeroen A C M, de Cuba, Erienne M V, Coupé, Veerle M H, Diosdado, Begoña, Delis-Van Diemen, Pien M, Karga, Cemile, Beliën, Jeroen A M, Menke-Van der Houven van Oordt, C Willemien, Geldof, Albert A, Meijer, Gerrit A, Hoekstra, Otto S, Fijneman, Remond J A, DeCoDe PET Group, Lam, MGEH, Borel Rinkes, IHM, van Diest, PJ, van Hillegersberg, R, Kranenburg, OW, Researchgr. Nucleaire Geneeskunde, Cancer, MS CGO, Regenerative Medicine and Stem Cells, Pathologie, Divisie Beeld & Oncologie, Goos, Jeroen A C M, de Cuba, Erienne M V, Coupé, Veerle M H, Diosdado, Begoña, Delis-Van Diemen, Pien M, Karga, Cemile, Beliën, Jeroen A M, Menke-Van der Houven van Oordt, C Willemien, Geldof, Albert A, Meijer, Gerrit A, Hoekstra, Otto S, Fijneman, Remond J A, DeCoDe PET Group, Lam, MGEH, Borel Rinkes, IHM, van Diest, PJ, van Hillegersberg, R, and Kranenburg, OW

Published
2016

7. Glucose Transporter 1 (SLC2A1) and Vascular Endothelial Growth Factor A (VEGFA) Predict Survival After Resection of Colorectal Cancer Liver Metastasis

Author

Goos, Jeroen A. C. M., primary, de Cuba, Erienne M. V., additional, Coupé, Veerle M. H., additional, Diosdado, Begoña, additional, Delis-Van Diemen, Pien M., additional, Karga, Cemile, additional, Beliën, Jeroen A. M., additional, Oordt, C. Willemien Menke-Van der Houven van, additional, Geldof, Albert A., additional, Meijer, Gerrit A., additional, Hoekstra, Otto S., additional, and Fijneman, Remond J. A., additional

Published
2016
Full Text
View/download PDF

9. A Low-Grade Trichoblastic Carcinoma Treated with Mohs Micrographic Surgery.

Author

Leeman A, de Cuba EMV, Jaspars LH, Quint KD, and Genders RE

Abstract

Trichoblastomas are rare dermal neoplasms usually found on the scalp and face. Histology shows a proliferation of small basaloid cells arranged in cords or fields surrounded by cellular stroma. Trichoblastomas are usually not aggressive, but trichoblastic carcinomas arising from preexisting trichoblastomas have been described and have been linked to basal cell carcinoma. We found a tumor with features of trichoblastoma with presence of Merkel cells, but with a deeply infiltrative growth pattern into the fat and muscle tissue, without significant architectural or cellular atypia. Tumors with similar growth patterns were previously described as deeply invasive trichoblastic neoplasms. It appears to be a new entity that has been described before but has not been fully characterized: low-grade trichoblastic carcinoma. This malignancy seems to show only locally aggressive growth. Radical excision was accomplished with Mohs micrographic surgery., Competing Interests: The authors report no conflict of interest., (Copyright © 2021 by S. Karger AG, Basel.)

Published
2021
Full Text
View/download PDF

10. [A patient with perfectly aligned itching papules of the back after hijama therapy].

Author

Wang D, van Praag MCG, and de Cuba EMV

Subjects
Administration, Topical, Adult, Beclomethasone administration & dosage, Biopsy, Dermatologic Agents administration & dosage, Female, Humans, Lichen Planus drug therapy, Lichen Planus pathology, Ointments, Paresthesia etiology, Skin pathology, Skin Diseases, Papulosquamous drug therapy, Skin Diseases, Papulosquamous etiology, Cupping Therapy adverse effects, Lichen Planus etiology, Pruritus etiology
Abstract

A 31-year-old woman was seen at our clinic with itching papules of the back after hijama treatments. Hijama treatments consist of superficially cutting the skin followed by cupping and are applied for a diversity of complaints, including pain. Our patient initially presented with sensitive and burning sensations at the cutting sites, but recently, the cutting sites started to itch as well. At physical examination, we saw perfectly aligned papules with a sign of Wickham's striae on her back where the skin had been cut. Further examination revealed comparable, solitary papules on the inside of her wrist, flank and chest. A skin biopsy confirmed the diagnosis lichen planus. The patient was prescribed betamethasone cream and we advised against further hijama treatments.

Published
2019

11. A prognostic classifier for patients with colorectal cancer liver metastasis, based on AURKA, PTGS2 and MMP9.

Author

Goos JA, Coupé VM, van de Wiel MA, Diosdado B, Delis-Van Diemen PM, Hiemstra AC, de Cuba EM, Beliën JA, Menke-van der Houven van Oordt CW, Geldof AA, Meijer GA, Hoekstra OS, and Fijneman RJ

Subjects
Case-Control Studies, Colorectal Neoplasms classification, Colorectal Neoplasms metabolism, Follow-Up Studies, Humans, Immunoenzyme Techniques, Liver metabolism, Liver Neoplasms classification, Liver Neoplasms metabolism, Neoplasm Staging, Prognosis, Survival Rate, Aurora Kinase A metabolism, Biomarkers, Tumor metabolism, Colorectal Neoplasms pathology, Cyclooxygenase 2 metabolism, Liver Neoplasms secondary, Matrix Metalloproteinase 9 metabolism
Abstract

Background: Prognosis of patients with colorectal cancer liver metastasis (CRCLM) is estimated based on clinicopathological models. Stratifying patients based on tumor biology may have additional value., Methods: Tissue micro-arrays (TMAs), containing resected CRCLM and corresponding primary tumors from a multi-institutional cohort of 507 patients, were immunohistochemically stained for 18 candidate biomarkers. Cross-validated hazard rate ratios (HRRs) for overall survival (OS) and the proportion of HRRs with opposite effect (P(HRR < 1) or P(HRR > 1)) were calculated. A classifier was constructed by classification and regression tree (CART) analysis and its prognostic value determined by permutation analysis. Correlations between protein expression in primary tumor-CRCLM pairs were calculated., Results: Based on their putative prognostic value, EGFR (P(HRR < 1) = .02), AURKA (P(HRR < 1) = .02), VEGFA (P(HRR < 1) = .02), PTGS2 (P(HRR < 1) = .01), SLC2A1 (P(HRR > 1) < 01), HIF1α (P(HRR > 1) = .06), KCNQ1 (P(HRR > 1) = .09), CEA (P (HRR > 1) = .05) and MMP9 (P(HRR < 1) = .07) were included in the CART analysis (n = 201). The resulting classifier was based on AURKA, PTGS2 and MMP9 expression and was associated with OS (HRR 2.79, p < .001), also after multivariate analysis (HRR 3.57, p < .001). The prognostic value of the biomarker-based classifier was superior to the clinicopathological model (p = .001). Prognostic value was highest for colon cancer patients (HRR 5.71, p < .001) and patients not treated with systemic therapy (HRR 3.48, p < .01). Classification based on protein expression in primary tumors could be based on AURKA expression only (HRR 2.59, p = .04)., Conclusion: A classifier was generated for patients with CRCLM with improved prognostic value compared to the standard clinicopathological prognostic parameters, which may aid selection of patients who may benefit from adjuvant systemic therapy.

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results